{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:23:17Z","timestamp":1793013797898,"version":"4.5.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/inf.0000000000001357","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T11:47:11Z","timestamp":1475840831000},"page":"445-450","source":"Crossref","is-referenced-by-count":17,"title":["Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005\u20132015)"],"prefix":"10.1097","volume":"36","author":[{"given":"Abby","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lanct\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosco A.","family":"Paes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210202","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/INF.0000000000000102","article-title":"Clinical characteristics and direct medical cost of respiratory syncytial virus infection in children hospitalized in Suzhou, China.","volume":"33","author":"Zhang","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R2-1-20210202","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12879-014-0544-x","article-title":"Social, economic, and health impact of the respiratory syncytial virus: a systematic search.","volume":"14","author":"D\u00edez-Domingo","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R3-1-20210202","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3111\/13696998.2012.672942","article-title":"Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.","volume":"15","author":"Weiner","year":"2012","journal-title":"J Med Econ"},{"key":"R4-1-20210202","doi-asserted-by":"crossref","first-page":"020416","DOI":"10.7189\/jogh.05.020416","article-title":"Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis.","volume":"5","author":"Shi","year":"2015","journal-title":"J Glob Health"},{"key":"R5-1-20210202","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12519-014-0513-x","article-title":"Clinical characteristics and risk factors of severe respiratory syncytial virus-associated acute lower respiratory tract infections in hospitalized infants.","volume":"10","author":"Zhang","year":"2014","journal-title":"World J Pediatr"},{"key":"R6-1-20210202","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/1874285801408010071","article-title":"Respiratory syncytial virus infection in high-risk infants - an update on palivizumab prophylaxis.","volume":"8","author":"Resch","year":"2014","journal-title":"Open Microbiol J"},{"key":"R7-1-20210202","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1586\/17476348.2015.1098536","article-title":"Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.","volume":"9","author":"Abraha","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"R8-1-20210202","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/1874285801105010144","article-title":"Risk factors for severe respiratory syncytial virus lower respiratory tract infection.","volume":"5","author":"Sommer","year":"2011","journal-title":"Open Microbiol J"},{"key":"R9-1-20210202","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0378-3782(12)70012-9","article-title":"High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention.","volume":"88","author":"Manzoni","year":"2012","journal-title":"Early Hum Dev"},{"key":"R10-1-20210202","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1017\/S104795110700042X","article-title":"Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: the CIVIC Epidemiologic Study.","volume":"17","author":"Medrano","year":"2007","journal-title":"Cardiol Young"},{"key":"R11-1-20210202","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1440-1754.2011.02219.x","article-title":"Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease.","volume":"48","author":"Alexander","year":"2012","journal-title":"J Paediatr Child Health"},{"key":"R12-1-20210202","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/apa.12658","article-title":"Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease.","volume":"103","author":"Granbom","year":"2014","journal-title":"Acta Paediatr"},{"key":"R13-1-20210202","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s002460010103","article-title":"Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening.","volume":"21","author":"Altman","year":"2000","journal-title":"Pediatr Cardiol"},{"key":"R14-1-20210202","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1097\/00003246-199909000-00042","article-title":"Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome.","volume":"27","author":"Khongphatthanayothin","year":"1999","journal-title":"Crit Care Med"},{"key":"R15-1-20210202","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s10096-016-2649-1","article-title":"Respiratory syncytial virus-associated hospitalizations over three consecutive seasons in children with congenital heart disease.","volume":"35","author":"Resch","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R16-1-20210202","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3345\/kjp.2011.54.5.192","article-title":"Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey.","volume":"54","author":"Jung","year":"2011","journal-title":"Korean J Pediatr"},{"key":"R17-1-20210202","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpeds.2004.03.029","article-title":"High risk of nosocomial-acquired RSV infection in children with congenital heart disease.","volume":"145","author":"Lanari","year":"2004","journal-title":"J Pediatr"},{"key":"R18-1-20210202","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jmii.2014.08.020","article-title":"Risk factors associated with death in patients with severe respiratory syncytial virus infection.","volume":"49","author":"Lee","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"R19-1-20210202","first-page":"782","article-title":"Mortality and morbidity of nosocomial respiratory syncytial virus (RSV) infection in ventilated children\u2013a ten year perspective.","volume":"78","author":"Thorburn","year":"2012","journal-title":"Minerva Anestesiol"},{"key":"R20-1-20210202","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1185\/03007995.2010.505126","article-title":"Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children.","volume":"26","author":"Welliver","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R21-1-20210202","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJM198208123070702","article-title":"Respiratory syncytial viral infection in infants with congenital heart disease.","volume":"307","author":"MacDonald","year":"1982","journal-title":"N Engl J Med"},{"key":"R22-1-20210202","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1526-0542(12)00095-4","article-title":"The risk of mortality among young children hospitalized for severe respiratory syncytial virus infection.","volume":"13","author":"Szabo","year":"2013","journal-title":"Paediatr Respir Rev"},{"key":"R23-1-20210202","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/HCO.0b013e32835dce2f","article-title":"Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab.","volume":"28","author":"Resch","year":"2013","journal-title":"Curr Opin Cardiol"},{"key":"R25-1-20210202","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"R26-1-20210202","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1203\/PDR.0b013e318220a553","article-title":"A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.","volume":"70","author":"Feltes","year":"2011","journal-title":"Pediatr Res"},{"key":"R27-1-20210202","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40121-014-0046-6","article-title":"Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review.","volume":"3","author":"Wegzyn","year":"2014","journal-title":"Infect Dis Ther"},{"key":"R28-1-20210202","doi-asserted-by":"crossref","first-page":"e0134711","DOI":"10.1371\/journal.pone.0134711","article-title":"Serious adverse events in the Canadian registry of children receiving palivizumab (CARESS) for respiratory syncytial virus prevention.","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"R29-1-20210202","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1442-200X.2006.02179.x","article-title":"Guidelines for the use of palivizumab in infants and young children with congenital heart disease.","volume":"48","author":"Nakazawa","year":"2006","journal-title":"Pediatr Int"},{"key":"R30-1-20210202","doi-asserted-by":"crossref","first-page":"199.e1","DOI":"10.1016\/j.anpedi.2014.10.004","article-title":"[Update of recommendations on the use of palivizumab as prophylaxis in RSV infections].","volume":"82","author":"Figueras Aloy","year":"2015","journal-title":"An Pediatr (Barc"},{"key":"R31-1-20210202","first-page":"222","article-title":"Statement of the German society of paediatric cardiology regarding RSV prophylaxis with palivizumab (synagis1) [in German].","volume":"152","author":"Schmaltz","year":"2004","journal-title":"Monatsschr Kinderheilkd"},{"key":"R32-1-20210202","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00112-005-1197-z","article-title":"Recommendations for RSV immune prophylaxis in infants and children with congenital heart disease [in German].","volume":"153","author":"Pinter","year":"2005","journal-title":"Monatsschr Kinderheilkd"},{"key":"R33-1-20210202","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13052-015-0203-x","article-title":"Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).","volume":"41","author":"Bollani","year":"2015","journal-title":"Ital J Pediatr"},{"key":"R35-1-20210202","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.arcped.2004.06.007","article-title":"[Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society].","volume":"11","author":"Chantepie","year":"2004","journal-title":"Arch Pediatr"},{"key":"R37-1-20210202","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1542\/peds.2014-1666","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.","volume":"134","year":"2014","journal-title":"Pediatrics"},{"key":"R38-1-20210202","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/pch\/20.6.321","article-title":"Preventing hospitalizations for respiratory syncytial virus infection.","volume":"20","author":"Robinson","year":"2015","journal-title":"Paediatr Child Health"},{"key":"R39-1-20210202","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/INF.0b013e31821146f7","article-title":"CARESS: the Canadian Registry of Palivizumab.","volume":"30","author":"Mitchell","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R40-1-20210202","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/INF.0000000000000922","article-title":"Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian Registry of Palivizumab.","volume":"34","author":"Chan","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R41-1-20210202","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1128\/AAC.06446-11","article-title":"Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.","volume":"56","author":"Robbie","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R42-1-20210202","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1067\/mpd.2000.110531","article-title":"Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid.","volume":"137","author":"Boyce","year":"2000","journal-title":"J Pediatr"},{"key":"R43-1-20210202","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/cid\/cir928","article-title":"Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study.","volume":"54","author":"Kristensen","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R44-1-20210202","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1185\/03007995.2015.1136606","article-title":"Trends in RSV bronchiolitis hospitalizations in children less than 1 year: 2004-2012.","volume":"32","author":"Sanchez-Luna","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"R45-1-20210202","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ppul.22781","article-title":"Predictors of severity and mortality in children hospitalized with respiratory syncytial virus infection in a tropical region.","volume":"49","author":"Rodr\u00edguez","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"R46-1-20210202","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ped.12051","article-title":"Morbidity and outcome of severe respiratory syncytial virus infection.","volume":"55","author":"El Kholy","year":"2013","journal-title":"Pediatr Int"},{"key":"R47-1-20210202","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/ppul.23102","article-title":"Efficacy of palivizumab prophylaxis among infants with congenital heart disease: a case control study.","volume":"50","author":"Ozyurt","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"R48-1-20210202","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/adc.2008.143057","article-title":"Risk factors for respiratory syncytial virus hospitalisation in children with heart disease.","volume":"94","author":"Kristensen","year":"2009","journal-title":"Arch Dis Child"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:12:36Z","timestamp":1620954756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201705000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001357","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}